We introduced and began commercial sales of FEMCON FE in the second half of 2006, but did not initiate promotional efforts in support of the product until ...
Total revenues for 2008 are expected to be in the range of $935 to $945 million, with the growth primarily being driven by LOESTRIN 24 FE, DORYX, FEMCON FE, ...
Total revenues for 2008 are expected to be in the range of $935 to $945 million, with the growth primarily being driven by LOESTRIN 24 FE, DORYX, FEMCON FE, ...
... is poised to post impressive revenue growth of 18% for 2007, aided by the successful 2006 product launches of Taclonex, Loestrin 24-Fe and Femcon-Fe. ...
Before we began shipping Femcon, which we then called Ovcon Fe chewable a year ago. You should note that we did not initiate full promotional support for ...
Before we began shipping Femcon, which we then called Ovcon Fe chewable a year ago. You should note that we did not initiate full promotional support for ...
We introduced and began commercial sales of FEMCON FE in the second half of 2006, but did not initiate promotional efforts in support of the product until ...
We introduced and began commercial sales of FEMCON FE in the second half of 2006, but did not initiate promotional efforts in support of the product until ...
The company claims that Watson subsidiary Watson Laboratories is infringing on the patent for the chewable oral contraceptive Femcon FE. ...
6667050 (the "050 Patent") which covers FEMCON FE, the first and only oral contraceptive that offers women the option of chewing their daily tablet. ...